Shield shares surge on expansion of US coverage for Accrufer
16th Dec 2021 15:21
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics updated the market on progress made on payer coverage of 'Accrufer' in the United States on Thursday.
Read moreShield Therapeutics appoints chief medical officer
27th Sep 2021 14:26
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics announced on Monday that Dr Jose Menoyo is joining its senior executive team as vice-president and chief medical officer, with immediate effect.
Read moreShield Therapeutics swings to losses in first half
17th Aug 2021 12:00
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics reported first-half revenues of £0.5m in its interim results on Tuesday, falling from £8.9m year-on-year.
Read moreShield Therapeutics inks exclusive licence for 'Accrufer' in Korea
12th Aug 2021 12:25
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics has entered into an exclusive licence agreement for 'Accrufer', it announced on Thursday, with Korea Pharma in South Korea.
Read moreShield Therapeutics appoints industry veteran Greg Madison as CEO
28th May 2021 13:37
(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced on Friday that Greg Madison has been appointed as its chief executive officer, with effect from 1 June.
Read moreShield taps Hans-Peter Rudolf as its new finance chief
22nd Mar 2021 08:18
(Sharecast News) - Commercial-stage pharmaceuticals company Shield Therapeutics announced on Monday that Hans-Peter Rudolf was joining its senior executive team as chief financial officer, with immediate effect.
Read moreShield's Feraccru gets registration in Australia
9th Mar 2021 15:56
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics said on Tuesday that Australia's Therapeutics Goods Administration (TGA) has registered 'Feraccru' in the country's Register of Therapeutic Goods, to treat iron deficiency with or without anaemia in adults.
Read moreShield shares rise as Teva withdraws patent oppositions
19th Oct 2020 09:12
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics updated the market on its opposition proceedings with Teva Pharmaceutical Industries on Monday, confirming that Teva had withdrawn its appeal and opposition over two of Shield's patents.
Read moreShield Therapeutics shares rise on two recent research papers
3rd Jun 2020 15:57
(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics reported the recent publication of two papers concerning its 'Feraccru' or 'Accrufer' product on Wednesday.
Read moreShield Therapeutics names Hans Peter Hasler as next chairman
26th May 2020 08:58
(Sharecast News) - Pharmaceutical group Shield Therapeutics named Hans Peter Hasler as non-executive chairman of the company on Tuesday.
Read moreShield Therapeutics FY revenues impacted by milestone repayment
1st May 2020 09:55
(Sharecast News) - Pharmaceuticals outfit Shield Therapeutics warned on Friday that full-year revenues would be lower than originally anticipated after it had to repay a sizeable milestone payment.
Read moreShield launches review after spotting flaw in 'Feraccru' study
17th Mar 2020 15:17
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics updated the market on the 'AEGIS-H2H' clinical trial on Tuesday, the data of which was primarily designed to be used in health economic analyses, pricing and reimbursement applications, as well as marketing purposes.
Read moreShield Therapeutics details year of 'material progress'
27th Jan 2020 08:09
(Sharecast News) - Drugs developer Shield Therapeutics told investors on Monday that 2019 had been a year of "material progress", with a key success being the recent Federal Drug Administration approval of its iron deficiency treatment, Feraccru/Accrufer.
Read moreShield Therapeutics narrows losses as it advances Feraccru to market
3rd Apr 2019 10:10
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics announced a decent improvement in revenue in its preliminary results on Wednesday, to £11.9m from £0.6m.
Read moreShield Therapeutics upbeat on latest Feraccru trial results
4th Mar 2019 11:26
(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced positive results from the AEGIS-H2H clinical trial on Monday, which compared 'Feraccru' (ferric maltol) - a novel oral iron replacement therapy - to 'Ferinject' (ferric carboxymaltose - FCM), the market-leading intravenously delivered iron replacement therapy.
Read more